Citizens JMP analyst Roy Buchanan raised the firm’s price target on Dynavax (DVAX) to $32 from $31 and keeps an Outperform rating on the shares. Dynavax continues to focus on priorities in HEPLISAV-B, business development, and the pipeline with the board battle behind it, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DVAX:
- Dynavax’s Strong Q2 Performance and Strategic Growth Justify Buy Rating
- Dynavax Technologies Reports Strong Q2 2025 Results
- Dynavax: Strong Heplisav Sales and Promising Vaccine Pipeline Justify Buy Rating
- Dynavax reports Q2 EPS 14c vs. 8c last year
- Dynavax raises 2025 Heplisav-B net product revenue view to $315M-$325M